The effect of thiamine supplementation in the treatment of gestational diabetes

The effect of thiamine supplementation on biomarkers of inflammation, oxidative stress and its related gene expression in patients with gestational diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N58

Enrollment

Registered

2019-05-24

Start date

2019-04-24

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: 100 mg thiamine (Shafa Pharmaceutical Company, Karaj, Iran) daily for 6 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), daily fo

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with gestational diabetes mellitus Individuals aged 18 to 40 years old

Exclusion criteria

Exclusion criteria: Overt diabetes mellitus Taking any supplements before the intervention Unwillingness to cooperate

Design outcomes

Primary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TGF-beta gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.	—

Measure

Time frame

Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TGF-beta gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Abed

Kashan University of Medical Sciences

abed.ar@gmail.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026